Anterogencoltd Stock EBITDA

065660 Stock  KRW 19,360  20.00  0.10%   
AnterogenCoLtd fundamentals help investors to digest information that contributes to AnterogenCoLtd's financial success or failures. It also enables traders to predict the movement of AnterogenCoLtd Stock. The fundamental analysis module provides a way to measure AnterogenCoLtd's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AnterogenCoLtd stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

AnterogenCoLtd Company EBITDA Analysis

AnterogenCoLtd's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current AnterogenCoLtd EBITDA

    
  (2.96 B)  
Most of AnterogenCoLtd's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AnterogenCoLtd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, AnterogenCoLtd reported earnings before interest,tax, depreciation and amortization of (2.96 Billion). This is 437.27% lower than that of the Healthcare sector and significantly lower than that of the Pharmaceuticals industry. The ebitda for all Republic of Korea stocks is 175.91% higher than that of the company.

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

AnterogenCoLtd Fundamentals

About AnterogenCoLtd Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze AnterogenCoLtd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AnterogenCoLtd using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AnterogenCoLtd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Other Information on Investing in AnterogenCoLtd Stock

AnterogenCoLtd financial ratios help investors to determine whether AnterogenCoLtd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AnterogenCoLtd with respect to the benefits of owning AnterogenCoLtd security.